Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TUL108 in Healthy Participants
NCT07719257Phase 1Not yet recruiting
- Sponsor
- The United Laboratories International Holdings
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TUL108 in complicated urinary tract infection (cUTI) (4 arms), sponsored by The United Laboratories International Holdings. Primary endpoint: Incidence of adverse events and serious adverse events. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
TUL108
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT07719257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719257.